Societal CDMO, Inc. Stock

Equities

SCTL

US75629F1093

Pharmaceuticals

Delayed Nyse 04:00:00 2024-04-05 pm EDT 5-day change 1st Jan Change
1.1 USD +0.92% Intraday chart for Societal CDMO, Inc. 0.00% +213.84%
Sales 2024 * 94.65M Sales 2025 * 101M Capitalization 116M
Net income 2024 * -9M Net income 2025 * - EV / Sales 2024 * 1.23 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.16 x
P/E ratio 2024 *
-12.2 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 61%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.92%
Current month+1.85%
1 month+0.92%
3 months+224.39%
6 months+181.98%
Current year+213.84%
More quotes
1 month
1.06
Extreme 1.06
1.10
Current year
0.31
Extreme 0.3078
1.10
1 year
0.26
Extreme 0.26
1.28
3 years
0.26
Extreme 0.26
3.15
5 years
0.26
Extreme 0.26
19.21
10 years
0.26
Extreme 0.26
19.21
More quotes
Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus in the area of small molecules. It is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company's key products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR and Donnatal liquids and tablets. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle potent compounds and controlled substances.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings